Literature DB >> 8786083

No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma.

R M Hofstra1, N C Cheng, C Hansen, R P Stulp, T Stelwagen, N Clausen, N Tommerup, H Caron, A Westerveld, R Versteeg, C H Buys.   

Abstract

Neuroblastoma occasionally occurs in diseases associated with abnormal neurocrest differentiation, e.g. Hirschsprung disease. Expression studies in developing mice suggest that the proto-oncogene RET plays a role in neurocrest differentiation. In humans expression of RET is limited to certain tumor types, including neuroblastoma, that derive from migrating neural crest cells. Mutations of RET are found associated with Hirschsprung disease. These data prompted us to investigate expression of RET and to search for gene mutations in neuroblastoma. Out of 16 neuroblastoma cell lines analyzed, 9 show clear expression of RET in a Northern blot analysis. In a single strandt conformation polymorphism (SSCP) analysis of all exons, no mutations were detected other than neutral polymorphisms. In a patient with neuroblastoma, from a family in which different neurocrestopathies, including neuroblastoma and Hirschsprung disease, had occurred, we also failed to detect RET mutations. Possibly, expression of RET in neuroblastoma merely reflects the differentiation status of the tumor cells. The absence of mutations suggests that RET does not play a crucial role in the tumorigenesis of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786083     DOI: 10.1007/bf02185773

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  30 in total

1.  ret transforming gene encodes a fusion protein homologous to tyrosine kinases.

Authors:  M Takahashi; G M Cooper
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

2.  Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture.

Authors:  J L Biedler; L Helson; B A Spengler
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

3.  Specific expression of the ret proto-oncogene in human neuroblastoma cell lines.

Authors:  I Ikeda; Y Ishizaka; T Tahira; T Suzuki; M Onda; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

4.  Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells.

Authors:  L Savelyeva; R Corvi; M Schwab
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

5.  Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification.

Authors:  H Caron; P van Sluis; M van Hoeve; J de Kraker; J Bras; R Slater; M Mannens; P A Voûte; A Westerveld; R Versteeg
Journal:  Nat Genet       Date:  1993-06       Impact factor: 38.330

6.  DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene.

Authors:  I Ceccherini; R M Hofstra; Y Luo; R P Stulp; V Barone; T Stelwagen; R Bocciardi; H Nijveen; A Bolino; M Seri
Journal:  Oncogene       Date:  1994-10       Impact factor: 9.867

7.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

8.  Expression of the ret proto-oncogene in human neuroblastoma cell lines and its increase during neuronal differentiation induced by retinoic acid.

Authors:  T Tahira; Y Ishizaka; F Itoh; M Nakayasu; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

9.  Expression of the c-ret proto-oncogene during mouse embryogenesis.

Authors:  V Pachnis; B Mankoo; F Costantini
Journal:  Development       Date:  1993-12       Impact factor: 6.868

10.  Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.

Authors:  T Iwamoto; M Taniguchi; W Wajjwalku; I Nakashima; M Takahashi
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more
  6 in total

Review 1.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 2.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

Review 3.  Multiple endocrine neoplasias type 2B and RET proto-oncogene.

Authors:  Giuseppe Martucciello; Margherita Lerone; Lara Bricco; Gian Paolo Tonini; Laura Lombardi; Carmine G Del Rossi; Sergio Bernasconi
Journal:  Ital J Pediatr       Date:  2012-03-19       Impact factor: 2.638

4.  Sparstolonin B, a novel plant derived compound, arrests cell cycle and induces apoptosis in N-myc amplified and N-myc nonamplified neuroblastoma cells.

Authors:  Ambrish Kumar; Daping Fan; Donald J Dipette; Ugra S Singh
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

5.  Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.

Authors:  Zhenghu Chen; Yanling Zhao; Yang Yu; Jonathan C Pang; Sarah E Woodfield; Ling Tao; Shan Guan; Huiyuan Zhang; Shayahati Bieerkehazhi; Yan Shi; Roma Patel; Sanjeev A Vasudevan; Joanna S Yi; Jodi A Muscal; Guo-Tong Xu; Jianhua Yang
Journal:  Oncotarget       Date:  2017-10-24

6.  Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma.

Authors:  Caroline D E Margetts; Mark Morris; Dewi Astuti; Dean C Gentle; Alberto Cascon; Fiona E McRonald; Daniel Catchpoole; Mercedes Robledo; Hartmut P H Neumann; Farida Latif; Eamonn R Maher
Journal:  Endocr Relat Cancer       Date:  2008-05-22       Impact factor: 5.678

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.